Zimmer Biomet Holdings – Consensus Indicates Potential 18.9% Upside Zimmer Biomet Holdings found using ticker (ZBH) have now 20 analysts in total covering the stock. The consensus rating is ''Hold''. The range between the high target price and low target price is between 145 and 114 calculating the mean target price we have 127. Now with the previous closing price of 106.8 this would indicate that there is a potential upside of 18.9%. The 50 day moving average now sits at 109.21 and the 200 moving average now moves to 117.65. The market cap for the company is $22,151m. Find out more information at: https:||www.zimmerbiomet.com [stock_market_widget type="chart" template="basic" color="green" assets="ZBH" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $26,340m based on the market concensus. Zimmer Biomet Holdings, together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.